Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
PTCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.00 - $54.16
Previous CloseN/A
Volume146.45K
Average Volume (3M)716.43K
Market Cap
$3.89B
Enterprise Value$2.24B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Feb 27, 2025EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.94
Shares Outstanding77,125,145
10 Day Avg. Volume702,945
30 Day Avg. Volume716,427
Standard Deviation0.13
R-Squared0.06
Alpha0.00011
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.32
Price to Cash Flow (P/CF)-12.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.57
Enterprise Value/Ebitda-21.21
Forecast
1Y Price Target
$61.00Price Target Upside21.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Financial PerformancePTCT reported 2024 total revenue of approximately $814M, which exceeds prior guidance of $750M to $800M.
Regulatory ApprovalThe NDA for vatiquinone in Friedreich's ataxia was accepted for review, with analysts anticipating rapid uptake in the pediatric population if approved.
Bears Say
Share Price OutlookThe stock rating is Sell / High Risk with an expected share price return of -7.5%.
---
Ownership Overview
1.41% Insiders
26.64% Mutual Funds
32.85% Other Institutional Investors
21.65% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $24.00 and its highest was $54.16 in the past 12 months.
What is PTC Therapeutics’s market cap?
PTC Therapeutics’s market cap is $3.89B.
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Feb 27, 2025 which is in 5 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on Nov 07, 2024. The company reported -$1.39 earnings per share for the quarter, beating the consensus estimate of -$1.521 by $0.131.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Undervalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is -0.54.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 77,125,145 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -$1.39 in its last earnings report, beating expectations of -$1.521. Following the earnings report the stock price went up 3.073%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Currently, no hedge funds are holding shares in PTCT
---
PTC Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$61.00 (21.08% Upside)
$61.00 (21.08% Upside)
Blogger Sentiment
Bullish
PTCT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 21.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
93.91%
12-Months-Change
Fundamentals
Return on Equity
42.98%
Trailing 12-Months
Asset Growth
46.22%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
---
PTCT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong financial performance, significant pipeline progress, and strategic NDA submissions and approvals. However, challenges remain in the European regulatory landscape and competitive pressures in the U.S. market.Read More>---
PTCT Stock 12 Month Forecast
Average Price Target
$61.00
▲(21.08% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Neurocrine
―
Sarepta Therapeutics
―
Best Analysts Covering PTCT
1 Year
1 Year Success Rate
14/17 ratings generated profit
1 Year Average Return
+34.56%
reiterated a buy rating 3 months ago
Copying Joel Beatty's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +34.56% per trade.
---